08:00 | Registration |
10:00 | The Biotech/CRO Relationship: Is the Niche CRO a Better Fit?
Albert Agro, CEO & President, HNZ Strategic Holdings, Canada
Small virtual biotechs often don’t have the internal expertise to manage studies and depend heavily on their partners in making such an initiative come to fruition. This discussion will focus on: the needs of the small biotech, the role of the niche CRO, a case study comparing the use of a global CRO and niche local providers for a small biotech and the future. |
10:30 | Coffee Break and Networking in the Exhibition Hall |
11:15 | Selecting the Right CMO Partner
David Downey, Vice President, Almac Group, United Kingdom
Choosing the most suitable CMO partner for your requirements can present challenges. Defining a selection criteria that captures your priorities will facilitate your choice and establish a level playing field that compares like with like. Secondly collating and providing a project information package that allows the CMO to assess the scope of work and quote accordingly will facilitate an initial screen. Direct supplier assessment over a range of considerations - technical, quality, operational and commercial, coupled to associated site visits will funnel choices further. Finally having chosen your preferred partner delivering on the project and managing the ongoing supply relationship becomes the means to move into a more strategic relationship. This presentation considers good practice in taking such decisions. |
11:45 |  | Keynote Presentation Discovery Chemistry Outsourcing: Optimising the Process
Luigi La Vecchia, Director, Novartis Institutes for BioMedical Research, Switzerland
The presentation will demonstrate how a small global network of preferred external suppliers was established, which criteria were applied to assess the various potential partners, the contracts set-up, which internal processes were implemented, and how the Prep Labs are collaborating with their current preferred suppliers. |
|
12:15 | Lunch and Networking in the Exhibition Hall |
13:30 | Poster Session |
|
Session: Selecting the Right Outsourcing Strategy |
| |
14:15 | In a Virtual World, Where Are the Walls of the House? The New Outsourcing
Katya Tsaioun, President, Apredica, United States of America
Industry Dilemma - In house resources or outsource it? Outsourcing differences: R&D, late preclinical, clinical. In this presentation I shall cover strategic sourcing, drivers for outsourcing, failed approaches to outsourcing, partnership-type relationship or straightforward outsourcing, how can a true win-win be achieved and examples from R&D outsourcing. |
14:45 | How to Obtain a Solid Track Record in Medicinal Chemistry Research Services
Bruno Giethlen, Chief Scientific Officer, Prestwick Chemicals, France
In this presentation, Dr. Giethlen will discuss the methods used by Prestwick Chemical, a successful medicinal chemistry research service provider, in order to reduce risks of failing in hit discovery, hit validation or lead optimization. In nine years of business, the company has been able to deliver six compounds that proceeded into clinical development. |
15:15 | Coffee Break and Networking in the Exhibition Hall |
16:00 | Preclinical Drug Safety: High Quality Data Obtained with a New Automated Patch Clamp Platform
Olaf Scheel, Study Director, Cytocentrics Bioscience GmbH, Germany
|
16:30 | Drug Discovery Outsourcing: The Importance of Integration in the Selection of Higher Quality Clinical Candidates
Simone Braggio, Director/Head, Aptuit Srl, Italy
Pharmaceutical and biotech industries are producing more drug candidates than ever before. Therefore the current need is not to increase the volume of drug candidates, but to improve drug discovery effectiveness advancing better candidates with greater frequency. In this context, the strategic outsourcing of lead optimization projects become challenging and the selection of a CRO partner that can guarantee the selection of higher quality clinical candidates is a key factor for success. |
17:00 | Drinks Reception |